PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC

NCT04809779 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Sintilimab

Sponsor

First Affiliated Hospital, Sun Yat-Sen University